Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and
current therapies that limit CKD progression and the development of cardiovascular disease …

Mineralocorticoid receptor (MR) activation in the heart and vessels leads to pathological
effects, such as excessive extracellular matrix accumulation, oxidative stress, and sustained …

Mineralocorticoid receptors (MRs) are implicated in the pathology of hypertension. MR
blockers are recommended for the treatment of salt-sensitive or resistant hypertension …

The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood
pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential …

Primary aldosteronism (PA) is the most common cause of secondary hypertension and is
associated with increased morbidity and mortality when compared with blood pressure …

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) are a new class of drugs
developed to address the medical need for effective and safer treatment to protect the kidney …

The steroidal mineralocorticoid receptor (MR) antagonists, spironolactone and eplerenone,
decrease blood pressure, and attenuate the progression of chronic kidney disease (CKD) …

Renin–angiotensin system inhibitors are recommended for treating hypertension with
chronic kidney disease. The addition of a mineralocorticoid receptor blocker may be one …

Cardiovascular disease accounts for more than 17 million deaths globally every year, of
which complications of hypertension account for 9.4 million deaths worldwide. Early …

There are limited data on the nighttime blood pressure (BP)-lowering effect of esaxerenone
and its effect on N-terminal pro b-type natriuretic peptide (NT-proBNP), a predictor of …